Skip to main content
. 2016 Apr 20;7(22):33025–33034. doi: 10.18632/oncotarget.8846

Figure 3. Preclinical orthotopic mouse models using RM9-Luc-pIRES-KLK3 cells (n = 7).

Figure 3

A. Bioluminescence images in a representative orthotopic mouse model. B. Tumor progression was monitored by evaluating serum PSA levels (ng/mL) (i) and bioluminescence intensity (photos/s) (ii) on days 3, 7, 14, and 21 after RM9-Luc-pIRES-KLK3 was injected into the prostate. Error bars represent standard error of mean. Mean values were analyzed among groups. *p < 0.05 C. Comparison between bioluminescence intensity and current methods of monitoring tumor size and serum PSA levels. The observed bioluminescent imaging (photos/sec) was proportional to the serum PSA (ng/ml) (R2 coefficient: 0.945). D. 18FFDG-PET images of orthotopic tumor-bearing mice on day 3 and day 14 after RM9-Luc-pIRES-KLK3 was injected into the prostate. E. Anatomical autoradiography images of the prostate and lung in the orthotopic prostate cancer model on days 3 and 14 after RM9-Luc-pIRES-KLK3 injection.